Kernicterus Treatment Market Growth Accelerates: Strategic Forecast Predicts $3.37 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Will the Kernicterus Treatment Industry Market Size Be by 2025?
Recent years have seen a constant expansion in the market for kernicterus treatment. The market, currently valued at $2.98 billion in 2024, is projected to reach $3.06 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.0%. Multiple factors contributed to this growth in the historical period, such as advancements in neonatal care procedures, heightened awareness amongst medical personnel, initiatives by the government to promote mother and child health, allocation of funds for research and clinical trials, as well as collaborations in the realm of medical research.

What's the Long-Term Growth Forecast for the Kernicterus Treatment Market Size Through 2029?
Stable expansion is anticipated for the kernicterus treatment market over the next few years, with a projected growth to $3.37 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 2.4%. Several factors contributing to this growth during the forecast period include ongoing medical education programs, worldwide health policies and initiatives, patient advocacy and support communities, collaborative international efforts in pediatric research, and governmental funding for neonatal health. Key trends to watch during this period are improvements in neonatal jaundice monitoring technology, the launch of sophisticated phototherapy devices, the creation of drugs to reduce bilirubin, a shift towards home-based phototherapy, the use of bilirubin nomograms and guidelines, and the incorporation of telehealth for distant monitoring.

View the full report here:
https://www.thebusinessresearchcompany.com/report/kernicterus-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Kernicterus Treatment Market Expansion?
The surge in neonatal jaundice cases is steering the growth path of the market for the treatment of kernicterus. Neonatal jaundice, usually referred to as simple jaundice in newborns, is a typical benign condition that results in the skin and whites of the baby's eyes turning yellow. The common remedy for neonatal jaundice is kernicterus treatment, which helps manage the symptoms and deliver supportive care by replacing the baby's blood with blood that has reduced bilirubin levels, thus enhancing the quality of life for the affected person. For example, the National Library of Medicine, a biomedical library situated in the US, stated in their October 2023 reports that roughly 60% of full-term infants and 80% of preterm infants exhibit jaundice symptoms within their first week, and approximately 10% of breastfed infants are still jaundiced at one month. Thus, the frequency of neonatal jaundice is predicted to fuel the growth of the kernicterus treatment market. Kernicterus Treatment Market Driver: Boost in Health Expenditure Propels Treatment Approaches

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13470&type=smp

What Are the Key Trends Driving Kernicterus Treatment Market Growth?
Leading organizations in the cornea treatment market are concentrating on forming collaborations to extend their influence and secure a strategic position in the market. For instance, in July 2024, the UCL Department of Medical Physics and Biomedical Engineering, an establishment based in the UK, committed to both scientific and educational endeavors in the sectors of medical physics and biomedical engineering. They did this in partnership with UCL Hospitals, a UK-based hospital, which initiated NeoSCB. This application, developed for smartphones, can identify severe jaundice in newborns by evaluating images of the sclera (the white part of the eye) and providing a non-intrusive screening technique. This system is particularly useful in areas with limited resources, as traditional jaundice screening tools can be expensive. The application quantifies the yellowness of the sclera and uses this information to estimate the bilirubin levels in the bloodstream. The application demonstrated an impressive accuracy rate, correctly diagnosing 74 out of 79 babies with severe jaundice. This is comparable to traditional methods like transcutaneous bilirubinometers, which measure bilirubin through the skin.

How Is the Kernicterus Treatment Market Segmented?
The kernicterus treatment market covered in this report is segmented -

1) By Treatment: Phototherapy, Intravenous Immunoglobulins (IVIG), Blood Transfusion, Medication, Other Treatments
2) By Symptoms: Jaundice, Unusual Eye Movements, Vomiting, Fever, Poor Feeding, Apnoea, Irritability, Seizures, Sleepiness, Other Symptoms
3) By Dosage: Injection, Solution, Other Dosages
4) By End-Users: Clinic, Hospital, Other End-Users

Subsegments:
1) By Phototherapy: Conventional Phototherapy, Fiberoptic Phototherapy, LED Phototherapy
2) By Intravenous Immunoglobulins (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
3) By Blood Transfusion: Exchange Transfusion, Simple Transfusion
4) By Medication: Bilirubin-Lowering Agents, Antioxidants, Neuroprotective Agents
5) By Other Treatments: Supportive Care, Nutritional Support, Adjunct Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13470&type=smp

Which Companies Are Leading the Charge in Kernicterus Treatment Market Innovation?
Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

Which Regions Are Leading the Global Kernicterus Treatment Market in Revenue?
North America was the largest region in the kernicterus treatment market in 2024. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13470

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.